Organon (OGN) reported $1.61 billion in revenue for the quarter ended June 2024, representing a year-overyear decline of 0.1%. EPS of $1.12 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -1.13% over the Zacks Consensus Estimate of $1.63 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +5.66%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

Organon & Co. (NYSE:OGN) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Jennifer Halchak - Head of IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Umer Raffat - Evercore ISI Ethan Brown - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Operator Thank you for standing-by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ...

Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.97 per share when it actually produced earnings of $1.22, delivering a surprise of 25.77%. Over the last four quarters, the co ...

Organon Second Quarter 2024 Earnings GANON™ Disclaimer statement Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management's expectations about Organon's future financial performance and prospects, including full-year 2024 guidance estimates and prediction ...

Exhibit 99.1 | --- | --- | --- | --- | |-------------------|------------------|----------------------|--------------------| | | | | | | Media Contacts: | Karissa Peer | Investor Contacts: | Jennifer Halchak | | | (614) 314-8094 | | (201) 275-2711 | | | Kate Vossen | | Renee McKnight | | | (732) 675-8448 | | (551) 204-6129 | Organon Reports Results for the Second Quarter Ended June 30, 2024 · Second quarter 2024 revenue of $1.607 billion, flat year-over-year on an as-reported basis and up 2% at constant curr ...

Organon & Co. (OGN) is scheduled to report second-quarter 2024 results on Aug 6, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of $1.22 surpassed the Zacks Consensus Estimate by 25.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 13.6%, on average. Let's check out the factors that have shaped OGN's performance prior to this announcement. Factor ...

Wall Street analysts expect Organon (OGN) to post quarterly earnings of $1.06 per share in its upcoming report, which indicates a year-over-year decline of 19.1%. Revenues are expected to be $1.63 billion, up 1.1% from the year-ago quarter. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 2.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. Before a company announces its earni ...

The latest trading session saw Organon (OGN) ending at $21.86, denoting a -1.84% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 1.08% for the day. Elsewhere, the Dow saw an upswing of 0.75%, while the tech-heavy Nasdaq appreciated by 2.64%. Shares of the pharmaceutical company witnessed a gain of 10.69% over the previous month, beating the performance of the Medical sector with its gain of 0.71% and the S&P 500's loss of 0.44%. Analysts and investors al ...

This pharmaceutical company is expected to post quarterly earnings of $1.11 per share in its upcoming report, which represents a year-over-year change of -15.3%. Revenues are expected to be $1.62 billion, up 1% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.96% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. ...

Investment Overview >$8bn. | Leverage ratio stable with 2023 year-end | --- | --- | --- | --- | --- | |---------------------------|----------|----------|----------|----------| | $ mil | Dec 2021 | Dec 2022 | Dec 2023 | Mar 2024 | | Cash and cash equivalents | 737 | 706 | 693 | 575 | | Gross Debt (1) | 9,134 | 8,913 | 8,760 | 8,714 | | Net Debt (1) | 8,397 | 8,207 | 8,067 | 8,139 | Furthermore, Organon's Established Brands division consists of >50 drugs whose patents are expiring, or have long since expired, ...